Who owns NewAmsterdam Pharma Co N.V. (NAMS)? Elite investor 13F holders

2 tracked elite investors reported holding NewAmsterdam Pharma Co N.V as of 2026-09-30, including Viking Global Investors, Maverick Capital. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

2 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Viking Global InvestorsNewamsterdam Pharma CompanySHARE2026-09-302026-11-16 00:00:0059922316.00 USD2463911.000000SharesreduceOriginal filing
Maverick CapitalNewamsterdam Pharma CompanySHARE2026-09-302026-11-16 00:00:0045128922.00 USD1855630.000000SharesreduceOriginal filing
Duquesne Family OfficeNewamsterdam Pharma CompanySHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing
D.E. ShawNewamsterdam Pharma CompanySHARE2026-09-302026-11-16 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown